Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571300 | 0.88 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2232390 | 0.85 | LMNA (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9368020 | 0.85 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7216773 | 0.83 | SMN1; SMN2 (0.55) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18256792 | 0.83 | CA12 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3956396 | 0.83 | CA1 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28759821 | 0.83 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5708227 | 0.83 | LMNA (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5177723 | 0.82 | LOXL2 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL13417829 | 0.82 | SMN1; SMN2 (0.54) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2549873-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | Merck Sharp & Dohme Corp. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2350020-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2011-07-21 | — | — | US | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1368295-A1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | F. Hoffman-la Roche AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002079134-A1 | PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CA1 4002/4885CA2 2119/4885CA12 4313/4885 |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GIPR | CA1 4122/4885CA2 2262/4885CA12 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.